Section 5 of 6
Economic information and modeling report
25 evidence topics · 39 sources
Modeling overview
Summary: price of darovasertib and drug cost inputs for the regimen and its comparators
No price, wholesale acquisition cost, budget impact model, or cost-effectiveness analysis of darovasertib or of the darovasertib plus crizotinib regimen was found. IDEAYA states that darovasertib, if approved for one or more designated indications, “may also be excluded from certain mandatory price negotiation provisions of the 2022 Inflation Reduction Act”.
- Crizotinib: Pfizer lists the wholesale acquisition cost of XALKORI at $23,773.10 per package of 60 capsules for both the 200 mg and 250 mg strengths, as Pfizer's published list price before any discount or rebate, accurate as of March 10, 2026. OptimUM-02 gives crizotinib 200 mg twice daily with darovasertib 300 mg twice daily; the XALKORI label's recommended dosage for ALK- or ROS1-positive metastatic NSCLC is 250 mg twice daily, with 200 mg twice daily as the first dose reduction. In OptimUM-02, median relative dose intensities were 91.0% for darovasertib and 77.1% for crizotinib, and median duration of treatment was 6.31 months.
- Tebentafusp: Immunocore lists KIMMTRAK 100 mcg/0.5 mL vial (NDC 80446-0401-01) at a wholesale acquisition cost of $22,050.00, effective 1 July 2026. The label dose is 20 mcg on Day 1, 30 mcg on Day 8, and 68 mcg on Day 15 and once every week thereafter, intravenously, until unacceptable toxicity or disease progression. CADTH notes that “Drug wastage is quite significant” because the standard dose is less than the vial size (68 mcg vs 100 mcg). Under the 2024 physician fee schedule, CMS granted KIMMTRAK an applicable percentage of unused or discarded product volume subject to refund of 45%, and Immunocore does not currently expect to make refund payments under the CMS Rule. Immunocore reports KIMMTRAK net revenue of $257.0 million in the United States for 2025.
- Pembrolizumab: Merck lists KEYTRUDA at $12,517.44 per dose given every 3 weeks and $25,034.88 per dose given every 6 weeks, current as of September 2026; the melanoma dose is 200 mg every 3 weeks or 400 mg every 6 weeks.
- No manufacturer-published U.S. list price of nivolumab, ipilimumab, dacarbazine, or the HEPZATO KIT was found. In the OptimUM-02 control arm, ipilimumab plus nivolumab was selected for 79 participants (76.7%) and pembrolizumab for 24, and no participant received dacarbazine; the topline release gives 76% (n=78) and 24% (n=25). Median duration of treatment was 2.87, 2.56, and 2.79 months for pembrolizumab, ipilimumab, and nivolumab.
- In Germany, the G-BA lists annual treatment costs per patient after statutory rebates of €605,881.61 to €619,990.00 for tebentafusp, €65,157.24 for ipilimumab, €75,915.32 to €76,207.30 for nivolumab, and €4,694.71 to €12,497.72 for dacarbazine.
Summary: eligible population inputs
- Incidence of uveal melanoma: IDEAYA estimates an annual incidence of primary uveal melanoma of more than 3,000 patients in the United States and more than 10,000 globally. Castle Biosciences estimates approximately 2,000 patients diagnosed annually with uveal melanoma in the United States. The American Cancer Society estimates about 3,200 new cancers of the eye and orbit, mainly melanomas, in the United States in 2026. In the United States from 1975 to 2020, the mean age-adjusted incidence of primary uveal melanoma was 5.6 per million population (95% CI, 5.5 to 5.7); the National Cancer Institute gives approximately 4.3 new cases per million people.
- Metastatic disease: IDEAYA estimates an annual incidence of newly diagnosed metastatic uveal melanoma of approximately 1,500 in the United States and 4,000 to 5,000 globally, based on data suggesting that approximately 50% of patients diagnosed in the primary setting progress to metastatic disease. Published estimates of the share of patients who develop metastases are up to 50% and 40% or more; after treatment for choroidal melanoma, 5- and 10-year cumulative metastasis rates were 25% (95% CI, 23% to 27%) and 34% (95% CI, 32% to 37%).
- HLA-A∗02:01 status: IDEAYA states that HLA∗A2(-) patients represent “between 60-65% of all mUM patients” and that loss of heterozygosity could lead to over-reporting of HLA∗A2(+) prevalence in blood-based testing. HLA-A∗02:01-negative patients comprised 49% of individuals prescreened for a trial of tebentafusp. In a U.S. real-world cohort of 219 participants with metastatic uveal melanoma (Tempus database, 2019-2025), HLA-A∗02:01 status was positive in 42.0%, negative in 42.9%, and unknown in 15.1%. Published articles state that HLA-A∗02:01-positive individuals account for 45% (or ~45%) of people in the United States and Europe, and that 40–50% of the European population express HLA-A∗02:01.
- Eligibility for tebentafusp: IDEAYA's presentation states “< 50% patients eligible for the only approved systemic therapy”, and Delcath states “Currently 55% of the patients are not eligible for KIMMTRAK”.
Summary: health technology assessments and cost-effectiveness analyses of tebentafusp
- NICE recommends tebentafusp for HLA-A∗02:01-positive unresectable or metastatic uveal melanoma only with the company's commercial arrangement; the list price is £10,114 per 200 microgram vial. The company's 3-state partitioned survival model used a starting age of 62 years, a 38-year time horizon, utility values by time to death, and the costs of HLA-A∗02:01 testing. With the end-of-life criteria, the acceptable ICER was around £39,000 per QALY gained; the ICERs are confidential. The resource impact report projects 120 to 125 people eligible each year, uptake of 25% in 2025-26 and 50% thereafter, and 60 people having tebentafusp each year from 2026-27, with pembrolizumab as the other treatment.
- The Scottish Medicines Consortium accepted tebentafusp for use within NHSScotland in the context of a Patient Access Scheme; the company's economic analysis used a partitioned survival model against pembrolizumab and nivolumab plus ipilimumab; the cost per year at list price is £525,928, and results in the pembrolizumab comparison showed a less favourable economic case.
- CADTH: at the sponsor-submitted price of $18,565 per vial, tebentafusp costs approximately $74,260 per 28-day cycle, and the ICER was $728,513 per QALY gained compared with investigator's choice of therapy; a price reduction of 91% would be required to reach $50,000 per QALY. In the CADTH base case, total costs and QALYs were $1,062,137 and 2.40 with tebentafusp and $147,736 and 1.14 with investigator's choice, and the ICER against nivolumab plus ipilimumab in previously untreated patients was $722,268 per QALY gained. Approximately 72% of OS and 92% of PFS with tebentafusp were accrued after the trial period by extrapolation. In the budget impact analysis from the perspective of a Canadian public health care payer, the 3-year budget impact for previously untreated patients was $32,731,194, and extending treatment duration by 1.9 months increased it to $77,670,205.
- In France, the Transparency Committee gave a favourable opinion for reimbursement and rated tebentafusp as providing a “moderate clinical added value (CAV III)”. In Germany, the G-BA found a “Hint for a considerable additional benefit” compared with dacarbazine, ipilimumab, and pembrolizumab, in approximately 100 to 130 eligible patients.
- A published analysis using a three-state partitioned survival model from the perspective of U.S. payers found an additional 0.47 QALYs (1.19 vs 0.72) and an incremental cost of $444,280 with tebentafusp, for an ICER of $953,230 per QALY against a willingness-to-pay threshold of $200,000 per QALY; tebentafusp became cost-effective at a unit price of $33.768 per µg.
- No assessment of uveal melanoma by the Institute for Clinical and Economic Review was found.
Summary: liver-directed therapy and revenue estimates
No cost-effectiveness study of radioembolization with yttrium-90 microspheres for uveal melanoma liver metastases was identified by a CADTH rapid response report, and none of chemosaturation by an NHS England evidence summary. Delcath estimates that 800 patients with uveal melanoma liver metastases in the United States and 1,200 in Europe may be eligible for HEPZATO or CHEMOSAT annually, an addressable market of approximately $600 million per year; the J-Code J9248 became effective on April 1, 2024, with transitional pass-through status under the Outpatient Prospective Payment System expiring on March 31, 2027. Truist analysts project around $800 million in peak revenue for darovasertib in first-line HLA-A2(-) metastatic uveal melanoma, and a second analyst estimate quoted by BioSpace is $415 million in peak revenues in the HLA-A∗02:01-negative population; Leerink notes that darovasertib could compete with KIMMTRAK in HLA-A∗02:01-positive uveal melanoma, an indication IDEAYA also intends to pursue.
Budget impact model or cost-effectiveness analysis of darovasertib plus crizotinib
No evidence found.
Darovasertib price
No evidence found.
Analyst estimates of peak revenue of darovasertib in first-line HLA-A∗02:01-negative metastatic disease
Company estimate of the annual incidence of primary and metastatic uveal melanoma and the HLA∗A2(-) share
Company statements on eligibility for the only approved systemic therapy and on other treatment options
Crizotinib wholesale acquisition cost, March 2026
| XALKORI package | Wholesale acquisition cost per package | Capsules per package |
|---|---|---|
| 200 mg capsules | “$23,773.10” | “60” |
| 250 mg capsules | “$23,773.10” | “60” |
Tebentafusp wholesale acquisition cost, effective July 2026
| Product | NDC | Updated wholesale acquisition cost, effective 1 July 2026 |
|---|---|---|
| KIMMTRAK (tebentafusp-tebn) 100 mcg/0.5 mL vial | “80446-0401-01” | “$22,050.00” |
Tebentafusp net revenue and treatment of discarded drug under Medicare Part B
Pembrolizumab list price, September 2026
Manufacturer-published United States list prices of nivolumab, ipilimumab, dacarbazine, and the HEPZATO KIT
No evidence found.
Annual treatment costs of tebentafusp and comparator therapies in Germany
| Therapy | Annual treatment costs per patient, after statutory rebates |
|---|---|
| Tebentafusp | “€ 605,881.61 - € 619,990.00” |
| Dacarbazine | “€ 4,694.71 - € 12,497.72” |
| Ipilimumab | “€ 65,157.24” |
| Lomustine | “€ 1,291.70” |
| Nivolumab | “€ 75,915.32 - € 76,207.30” |
| Pembrolizumab | “€ 97, 656.46” |
Added benefit and target population of tebentafusp in the German benefit assessment
| Item | Quoted record |
|---|---|
| Extent and probability of the additional benefit of tebentafusp compared to dacarbazine, ipilimumab and pembrolizumab | “Hint for a considerable additional benefit” |
| Number of HLA-A∗02:01-positive adult patients with unresectable or metastatic uveal melanoma eligible for treatment in Germany | “approx. 100 - 130 patients” |
Tebentafusp list price and commercial arrangement in England
NICE cost-effectiveness model structure, utilities, and testing costs for tebentafusp
NICE end-of-life criteria, acceptable cost-effectiveness ratio, and decision for tebentafusp
Population expected to be eligible for and to receive tebentafusp in England
Scottish Medicines Consortium advice, economic model, and annual list-price cost of tebentafusp
| Medicine | Cost per year at list price, £ |
|---|---|
| Tebentafusp | “525,928” |
CADTH cost-effectiveness estimate, required price reduction, and cost per cycle of tebentafusp
CADTH appraisal of the sponsor cost-utility model: comparator costs, structure, and health utilities
CADTH appraisal of the sponsor budget impact analysis: treatment duration, market share, and 3-year budget impact
French Transparency Committee assessment of tebentafusp
Cost-effectiveness of tebentafusp from a United States payer perspective
“A three-state partitioned survival model was developed to assess the costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) from the perspective of US payers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with control group, tebentafusp therapy yielded an additional 0.47 QALYs (1.19 vs. 0.72 QALYs) and an incremental cost of $444 280 ($633 822 vs. $189 542).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The resultant ICER of $953 230/QALY far outweighed the willingness-to-pay threshold of $200 000/QALY.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Scenario analyses indicated that reducing the unit price of tebentafusp to $33.768/µg was associated with a favorable result of tebentafusp being cost-effective.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Institute for Clinical and Economic Review assessment in uveal melanoma
No evidence found.
Cost-effectiveness of liver-directed therapy for uveal melanoma liver metastases
Company estimate of the population eligible for melphalan percutaneous hepatic perfusion and its reimbursement codes
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.